Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acromegaly
Indevus Announces Initiation of Phase III Clinical Trial of Octreotide Implant for Acromegaly
October 17th, 2008
Indevus Pharmaceuticals, Inc. (NASDAQ:IDEV) announced the initiation of a Phase III clinical trial of the Company's novel octreotide implant for acromegaly. This trial is designed to test the efficacy, safety and tolerability of the octreotide implant in patients with acromegaly. The implant utilizes the Company's patented HYDRON(R) Polymer Technology to deliver effective levels of octreotide for six months. Octreotide is a synthetic peptide that mimics the natural hormone somatostatin to suppress release of growth hormone (GH). Approximately 34 clinical sites in six countries are participating in this open-label Phase III trial. Participants in the trial will be...
Source: Health Business Week (2008-10-17)
|
